Nimesh Patel, MD

Nimesh Patel, MD, urges the FDA to reconsider SYD-101 as pediatric myopia drives earlier retinal damage in US children.

Nimesh A. Patel, MD, explains why myopia-related retinal detachments are appearing earlier and how routine exams can catch them.

Nimesh A. Patel, MD, discusses compounded low-dose atropine and SYD-101 ahead of an October 30 FDA advisory committee meeting.

At Retina Society 2026, Nimesh Patel, MD, discusses how stage 2 ROP before 34 weeks raises the treatment rate and why he urges early referral and a risk-tailored approach to care.

A real-world Vestrum database analysis found pegcetacoplan was linked to better visual acuity outcomes in geographic atrophy, including in patients with concurrent neovascular AMD, per Nimesh Patel, MD, at ASRS 2026.